Stay updated on Entinostat + Pembrolizumab in Lymphomas Clinical Trial
Sign up to get notified when there's something new on the Entinostat + Pembrolizumab in Lymphomas Clinical Trial page.

Latest updates to the Entinostat + Pembrolizumab in Lymphomas Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedAdded a dedicated 'Locations' section listing study sites in Illinois, New Jersey, and New York. Removed the separate 'Illinois Locations', 'New Jersey Locations', and 'New York Locations' subsections.SummaryDifference0.4%

- Check29 days agoNo Change Detected
- Check50 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check57 days agoChange DetectedThe government funding notice banner has been removed from the page, with no other visible changes to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange DetectedScreenshots show only cosmetic/layout differences with no changes to core study content such as title, conditions, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check100 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference3%

- Check107 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.1%

Stay in the know with updates to Entinostat + Pembrolizumab in Lymphomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Entinostat + Pembrolizumab in Lymphomas Clinical Trial page.